Forrest Graeme N, Wagner Lee-Ann M, Talwani Rohit, Gilliam Bruce L
Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
J Int Assoc Physicians AIDS Care (Chic). 2009 Nov-Dec;8(6):338-41. doi: 10.1177/1545109709352883.
Non-typhoidal salmonella (NTS) bacteremia is a significant cause of morbidity and mortality in HIV-infected individuals worldwide. Recent reports have noted increasing resistance of NTS isolates to fluoroquinolones, the recommended first-line therapy for NTS bacteremia. The outcomes and risk factors for NTS bacteremia in HIV-infected patients in an urban US setting were evaluated. From January 2002 to December 2006, 26 episodes of NTS bacteremia were identified in 16 patients. The risk factors for NTS bacteremia were low CD4 count, high viral load, and lack of antiretroviral therapy (ART). Recurrences appeared related to lack of immune reconstitution in patients not on ART. Unlike reports from Asia, no fluoroquinolone resistance was identified in any of the Salmonella strains isolated in this setting. Optimal treatment of NTS in the HIV-infected patient in the United States should include therapy with fluoroquinolones as well as attaining complete viral suppression and immune reconstitution with ART.
非伤寒沙门菌(NTS)菌血症是全球HIV感染者发病和死亡的重要原因。最近的报告指出,NTS分离株对氟喹诺酮类药物的耐药性不断增加,而氟喹诺酮类药物是推荐用于治疗NTS菌血症的一线疗法。对美国城市地区HIV感染患者发生NTS菌血症的结局和危险因素进行了评估。2002年1月至2006年12月,在16例患者中确定了26次NTS菌血症发作。NTS菌血症的危险因素包括CD4计数低、病毒载量高以及未接受抗逆转录病毒治疗(ART)。复发似乎与未接受ART治疗患者的免疫重建不足有关。与亚洲的报告不同,在此环境中分离出的任何沙门菌菌株均未发现氟喹诺酮耐药性。在美国,HIV感染患者的NTS最佳治疗应包括氟喹诺酮类药物治疗,以及通过ART实现完全的病毒抑制和免疫重建。